Neoadjuvant Chemotherapy In Locally Advanced Gastric-cancer - Preliminary-results of A Phase-ii Trial With A Modified Famtx Combination
| العنوان: | Neoadjuvant Chemotherapy In Locally Advanced Gastric-cancer - Preliminary-results of A Phase-ii Trial With A Modified Famtx Combination |
|---|---|
| المؤلفون: | Francesco Caponigro, G. Benassai, Rosario Vincenzo Iaffaioli, A. Tortoriello, G. Sarnella, G. Persico, Luigi Bucci, G. Facchini, D. Giglio, G. Gesue |
| المساهمون: | G., Facchini, A., Tortoriello, F., Caponigro, Benassai, Giacomo, Bucci, Luigi, G., Gesue, G., Sarnella, D., Giglio, G., Persico, R. V., Iaffaioli |
| المصدر: | Europe PubMed Central ResearcherID |
| سنة النشر: | 1995 |
| مصطلحات موضوعية: | Oncology, Cancer Research, Chemotherapy, medicine.medical_specialty, Leukopenia, business.industry, medicine.medical_treatment, Locally advanced, Cancer, General Medicine, medicine.disease, law.invention, Regimen, Randomized controlled trial, law, Internal medicine, medicine, Methotrexate, Doxorubicin, medicine.symptom, business, medicine.drug |
| الوصف: | Twenty-two patients with locally advanced inoperable gastric cancer received neoadjuvant chemotherapy with a modified 5-fluorouracil, doxorubicin, methotrexate (FAMTX) regimen. The patients who achieved at least a stable disease were considered eligible for surgery with curative intent, which was performed in 19 cases. 16 patients (all responsive to neoadjuvant chemotherapy) were rendered disease-free by the combined approach. No treatment-rel ated deaths occurred; grade III leukopenia was observed in only 3 cases. The preliminary results of this study indicate the feasibility of our treatment approach; randomized trials are awaited to properly evaluate the role of neoadjuvant chemotherapy in locally advanced gastric cancer. locally advanced gastric cancer, with the aim of evaluating the ability of such an approach to decrease the tumor mass, to improve the resectability rate and, ultimately, to have a favourable impact on overall survival. The regimen including 5-fluorouracil, doxorubicin, methotrexate (FAMTX) was chosen as neoadjuvant treatment for our study, given its high efficacy in advanced gastric cancer and its lower toxicity when compared with other active regimens (5). We report on the preliminary results of our study, which mainly focus on resectability as therapeutic endpoint. In the future, we plan to report on the definitive results of our study, including the effects of preoperative chemotherapy on survival of patients. |
| وصف الملف: | STAMPA |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53da895cb633aa9b0986b549e3cb38b7 http://hdl.handle.net/11588/420802 |
| حقوق: | CLOSED |
| رقم الأكسشن: | edsair.doi.dedup.....53da895cb633aa9b0986b549e3cb38b7 |
| قاعدة البيانات: | OpenAIRE |
| الوصف غير متاح. |